We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer (APPROVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04348032
Recruitment Status : Active, not recruiting
First Posted : April 15, 2020
Last Update Posted : March 31, 2022
Jiangsu HengRui Medicine Co., Ltd.
Information provided by (Responsible Party):
Ling-Ying Wu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Brief Summary:
Epithelial ovarian cancer is the most fatal gynecological malignancy. Despite initial therapeutic response, the majority of advanced-stage patients relapse and eventually succumb to chemoresistant disease. The prognosis of patients with platinum-resistant or refractory ovarian cancer was very poor, with the response rate of 20%~25% after chemotherapy. The purpose of treatment for recurrent ovarian cancer is mainly to improve the quality of life of patients and prolong survival. Angiogenesis is essential for tumor growth and metastasis.And VEGF/VEGF receptor(VEGFR) signaling pathway is the most promising angiogenic target due to its key roles in angiogenesis and tumor growth.This study sought to assess the efficacy and safety of the combination therapy of apatinib and PLD, clarifying whether combination therapy could improve the outcomes of patients with platinum-resistant recurrent ovarian cancer.

Condition or disease Intervention/treatment Phase
Platinum-resistant Recurrent Ovarian Cancer Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd Drug: PLD 40mg/m2 ivgtt q4w Phase 2

Detailed Description:
This study is a randomized, parallel-controlled, multicenter clinical study. We recruit patients over the age of 18 years with platinum-resistant recurrent ovarian cancer. patients who meet the criteria for enrollment are randomly divided into two groups, including experiment group and control group. This study will be divided into three stages: 1. Baseline period (within 21 days before the start of treatment): Patients will complete screening tests during the baseline period to assess whether they meet the selection criteria. 2. Treatment period (from the first administration to the completion of the last treatment cycle). The tumor will be evaluated every 8 weeks during this period. If the treatment is effective, the chemotherapy does not exceed 6 cycles,then experiment group receives oral apatinib maintenance therapy until the disease progresses or toxicity could not be tolerated. Control group is followed up. 3. Follow-up period. After the end of chemotherapy, the survival status and follow-up anti-tumor therapy are collected by telephone or research centers visit every 3 months until death or loss of follow-up.The primary endpoint is the progression-free survival time(PFS) of patients and is judged according to Response Evaluation Criteria in Solid Tumors, version 1.1. Adverse events are classified and recorded according to the National Cancer Institute's Standard of Common terms for adverse reactions (NCI-CTCAE) version 4.0.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer(APPROVE): a Randomized, Controlled, Open-label, Phase 2 Trial
Actual Study Start Date : March 22, 2018
Actual Primary Completion Date : January 28, 2021
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Arm Intervention/treatment
Active Comparator: PLD
PLD 40 mg/m2 D1 ivgtt q4w
Drug: PLD 40mg/m2 ivgtt q4w
The dose of intravenous chemotherapy drug is calculated according to the body surface area. When patients have serious adverse reactions, dose suspension and dose reduction are allowed. The PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%).

Experimental: PLD + Apatinib
PLD 40 mg/m2 D1 ivgtt q4w + Apatinib 250mg po qd
Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd
Patients receive PLD and apatinib at the same time. The dose of intravenous chemotherapy drug is calculated according to the body surface area, and the dose of oral drug apatinib is 250mg qd. Dose suspension and dose reduction are allowed only when patients have serious adverse reactions. The intravenous chemotherapy drug PLD dose is only allowed to be down-regulated twice (one time is to reduce the standard dose by 25%), and the oral drug apatinib dose is only allowed to be reduced once (250mg gravity QD changed to 250mg gravity Qod). Otherwise the patients will drop out of the study.

Primary Outcome Measures :
  1. Progression-free Survival(PFS) [ Time Frame: up to 2 years ]
    From date of randomization until the date of first documented progression or died

Secondary Outcome Measures :
  1. Overall survival(OS) [ Time Frame: up to 2 years ]
    From date of randomization until the date of death from any cause

  2. Objective response rate(ORR) [ Time Frame: up to 2 years ]
    The proportion of patients with tumor shrinkage reaching a certain amount and for a certain period of time, including cases of CR PR.

  3. disease control rate(DCR) [ Time Frame: up to 2 years ]
    including CR, PR, SD

  4. hematological toxicity and non-hematological toxicity [ Time Frame: up to 2 years ]
    including hematological toxicity and non-hematological toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Patients were diagnosed with ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by previous pathology, and the pathological type was non-mucinous adenocarcinoma.There were previous surgical wax preservation.
  2. Initial platinum-resistant relapse, the recurrence time was less than 6 months after the last chemotherapy.
  3. Complicated with malignant pleural effusion or ascites, or with recurrent lesions that can be evaluated clinically.
  4. ECOG physical status score 0 or 1.
  5. The expected survival time is ≥ 4 months.
  6. In the previous treatment, there was no antivascular targeted therapy;
  7. Patients without pleural effusion or ascites should be confirmed by CT or MRI according to the standard of RECIST1.1 version, requiring the patient to have at least one measurable focus as the target focus. If the target focus is a lymph node with a short diameter of more than 1.5 cm, and the target focus is not suitable for surgical treatment, the target focus has not received radiotherapy or relapsed in the radiotherapy field.
  8. The baseline blood routine conforms to the following criteria:

    1. neutrophil count ≥ 1.5x109 /L;
    2. platelet count ≥ 100x109 PG L;
    3. hemoglobin ≥ 9g/dL (blood transfusion is allowed to achieve or maintain this target) .
  9. Liver function meets the following criteria:

    1. total bilirubin<1.5 normal limit (ULN);
    2. glutamic oxaloacetic transaminase (AST), glutamic pyruvic transaminase (ALT)<2.5xULN, which is allowed<5xULN in patients with liver metastasis.
  10. Serum creatinine ≤ 1.25xULN or calculated creatinine clearance ≥ 50mL/min.

Exclusion criteria

  1. Have received more than two chemotherapy regimens in the past.
  2. Currently or recently (within 30 days before enrollment) using another research drug or participating in another clinical study.
  3. other malignant tumors have occurred within 5 years (except adequately treated cervical carcinoma in situ or skin squamous cell carcinoma, or controlled basal cell carcinoma of the skin).
  4. Patients with hypertension that cannot be reduced to normal range after antihypertensive treatment (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90 mmHg).
  5. Suffer from myocardial ischemia or myocardial infarction above II grade and poorly controlled arrhythmias (including QTc interval ≥ 470ms in females).
  6. According to the NYHA standard, there were previous or present cardiac insufficiency of grade II or above, or color Doppler echocardiography showed that the left ventricular ejection fraction ((LVEF)) was less than 50% or the lower limit of the normal value.
  7. Abnormal coagulation function (INR>1.5 or prothrombin time (PT) > ULN+4 seconds or APTT>1.5xULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy.
  8. There were significant clinical bleeding symptoms or definite bleeding tendency in the first 3 months, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood or above, or suffering from vasculitis.
  9. Major surgical operations or severe traumatic injuries, fractures or ulcers occurred within the first 4 weeks of randomization.
  10. There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction.
  11. Urine routine indicates urinary protein ≥++, or confirms 24-hour urinary protein ≥ 1.0g.
  12. The researchers judged other conditions that may affect the conduct of clinical studies and the determination of research results.
  13. Allergic or heterogeneous reactions to doxorubicin and / or related substances.
  14. The cumulative dose of doxorubicin (including previous anthracycline, if any) is expected to reach or exceed 550 mg after 4 courses of doxorubicin liposome injection treatment.
  15. Uncontrollable arrhythmias or electrocardiograms abnormalities determined by the lead researcher to be at risk.
  16. A history of doxorubicin liposome therapy in recent half a year.
  17. Have previously received local radiotherapy of the pelvis or lower abdomen.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04348032

Layout table for location information
China, Beijing
National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing, China, 100021
Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University
Beijing, Beijing, China
Peking Union Medical College Hospital
Beijing, Beijing, China
Peking University Cancer Hospital
Beijing, Beijing, China
China, Chongqing
Chongqing Cancer Hospital
Chongqing, Chongqing, China, 400030
China, Guangxi
Guangxi Cancer Hospital
Guangxi, Guangxi, China
China, Hubei
Hubei Cancer Hospital
Hubei, Hubei, China
China, Hunan
Hunan Cancer Hospital
Hunan, Hunan, China
Xiangya Hospital of Central South University
Hunan, Hunan, China
China, Jilin
The first Hospital of Jilin University
Jilin, Jilin, China
China, Liaoning
Liaoning Cancer Hospital
Liaoyang, Liaoning, China
China, Shangdong
Shandong Cancer Hospital
Shangdong, Shangdong, China
China, Shanghai
Tumor Hospital affiliated to Fudan University
Shanghai, Shanghai, China
China, Sichuan
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China, 100021
China, Tianjin
Tumor Hospital of Tianjin Medical University
Tianjin, Tianjin, China
China, Yunnan
Yunnan Cancer Hospital
Yunnan, Yunnan, China
Sponsors and Collaborators
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jiangsu HengRui Medicine Co., Ltd.
Layout table for investigator information
Study Chair: Lingying Wu, MD Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ling-Ying Wu, chief physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ClinicalTrials.gov Identifier: NCT04348032    
Other Study ID Numbers: 2016YFC1303704
First Posted: April 15, 2020    Key Record Dates
Last Update Posted: March 31, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make individual participant data (IPD) available to other researchers

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Disease Attributes
Pathologic Processes
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action